TAP Block With Two Different Doses of Levobupivacaine
Primary Purpose
Pain, Postoperative
Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Levobupivacaine
Sponsored by
About this trial
This is an interventional supportive care trial for Pain, Postoperative
Eligibility Criteria
Inclusion Criteria:
- Volunteers planned to undergo unilateral inguinal surgery under TAP (ilioinguinal and iliohypogastric block) and general anesthesia
- Aged between 2 and 12
Exclusion Criteria:
- Patients with coagulation dysfunction
- Patients with chronic pain
- Patients having infection at the site of intervention
- Patients with a history of allergy
- Patients having chronic diseases (hepatic dysfunction, renal failure)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Group Levobupivacaine high volume
Group Levobupivacaine low volume
Arm Description
TAP block with levobupivacaine 0.25% of 0.5 ml/kg under general anesthesia
TAP block with levobupivacaine 0.25% of 0.25 ml/kg under general anesthesia
Outcomes
Primary Outcome Measures
postoperative VAS score <4 at postoperative 24 hours
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02567487
Brief Title
TAP Block With Two Different Doses of Levobupivacaine
Official Title
Comparison of TAP Block With Two Different Doses of Levobupivacaine for Postoperative Pain Management in Pediatric Patients
Study Type
Interventional
2. Study Status
Record Verification Date
October 2015
Overall Recruitment Status
Unknown status
Study Start Date
July 2015 (undefined)
Primary Completion Date
January 2016 (Anticipated)
Study Completion Date
July 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ankara University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of the current study is to investigate the effects of two different doses of levobupivacaine in TAP (transversus abdominus plane) block for postoperative management. For this purpose we planned to include 50 children aged between 2 and 12 that will undergo unilateral inguinal surgery.
The doses that will be used in the study were within usual dose limits which is stated in prospectus of the study drug.
Detailed Description
Fifty children undergoing TAP block were randomly divided into two groups as levobupivacaine 0.25% 0.5 ml/kg and levobupivacaine 0.25% 0.25 ml/kg. Postoperative pain was evaluated with observational pain scale and modified pediatric objective pain scale.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group Levobupivacaine high volume
Arm Type
Active Comparator
Arm Description
TAP block with levobupivacaine 0.25% of 0.5 ml/kg under general anesthesia
Arm Title
Group Levobupivacaine low volume
Arm Type
Active Comparator
Arm Description
TAP block with levobupivacaine 0.25% of 0.25 ml/kg under general anesthesia
Intervention Type
Drug
Intervention Name(s)
Levobupivacaine
Other Intervention Name(s)
Chirocaine
Intervention Description
Transversus abdominis plane block with levobupivacaine
Primary Outcome Measure Information:
Title
postoperative VAS score <4 at postoperative 24 hours
Time Frame
Postoperative first 24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Volunteers planned to undergo unilateral inguinal surgery under TAP (ilioinguinal and iliohypogastric block) and general anesthesia
Aged between 2 and 12
Exclusion Criteria:
Patients with coagulation dysfunction
Patients with chronic pain
Patients having infection at the site of intervention
Patients with a history of allergy
Patients having chronic diseases (hepatic dysfunction, renal failure)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Neslihan Alkis
Organizational Affiliation
Ankara University Medical Faculty
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
TAP Block With Two Different Doses of Levobupivacaine
We'll reach out to this number within 24 hrs